Jim Simons
DERM icon

Jim Simons’s Journey Medical DERM Stock Holding History

Jim Simons’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Sell
242,500
-1,500
-0.6% -$11.6K ﹤0.01% 2201
2025
Q4 		$1.88M Sell
244,000
-3,900
-2% -$30.6K ﹤0.01% 1902
2025
Q3 		$1.77M Buy
247,900
+4,400
+2% +$31.9K ﹤0.01% 2156
2025
Q2 		$1.75M Buy
243,500
+5,500
+2% +$38K ﹤0.01% 2198
2025
Q1 		$1.4M Buy
238,000
+2,000
+0.8% +$9.83K ﹤0.01% 2203
2024
Q4 		$923K Sell
236,000
-32,200
-12% -$176K ﹤0.01% 2539
2024
Q3 		$1.52M Buy
268,200
+4,175
+2% +$21.5K ﹤0.01% 2194
2024
Q2 		$1.49M Sell
264,025
-6,575
-2% -$27.1K ﹤0.01% 2072
2024
Q1 		$996K Buy
270,600
+9,600
+4% +$41.8K ﹤0.01% 2486
2023
Q4 		$1.5M Buy
261,000
+240,100
+1,149% +$1.07M ﹤0.01% 2132
2023
Q3 		$57K Buy
20,900
+9,400
+82% +$21K ﹤0.01% 3378
2023
Q2 		$18K Buy
+11,500
New +$18.5K ﹤0.01% 3784
2022
Q2 		– Sell
-15,600
Closed -$75K – 4285
2022
Q1 		$75K Buy
+15,600
New +$77.9K ﹤0.01% 3843

Other funds holding DERM

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jim Simons's DERM Position: Q1 2026 in Review

Jim Simons reduced its Journey Medical (DERM) stake by 0.61% in Q1 2026, selling an estimated $11.6K and leaving 242,500 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

Jim Simons first reported a position in DERM in Q1 2022 and has held it in 13 quarters since. The position peaked at $1.88M in Q4 2025. 72 funds tracked by Wall St. Rank hold DERM as of Q1 2026.

  • Jim Simons held 242,500 shares of Journey Medical worth $1.14M as of Q1 2026.
  • Jim Simons sold 1,500 Journey Medical shares in Q1 2026, an estimated $11.6K.
  • Journey Medical made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2201 holding.
  • Jim Simons first reported a position in Journey Medical in Q1 2022 and has held it in 13 quarters since.
  • Jim Simons's Journey Medical position peaked at $1.88M in Q4 2025.
  • 72 funds tracked by Wall St. Rank held Journey Medical as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.